Ignite Creation Date:
2025-12-24 @ 5:25 PM
Ignite Modification Date:
2026-03-28 @ 2:23 PM
Study NCT ID:
NCT01084668
Status:
COMPLETED
Last Update Posted:
2012-06-29
First Post:
2010-02-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs
Sponsor:
Abbott
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Psoriasis Chronic | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | monoclonals | View |
| None | moderate to severe chronic plaque psoriasis | View |
| None | adalimumab | View |
| None | Psoriasis Area and Severity Index (PASI) | View |
| None | Disease Life Quality Index (DLQI) | View |
| None | Nail Psoriasis Severity Index (NAPSI) | View |
| None | biologic disease modifying anti-rheumatic drug (BDMARD) | View |
| None | antibodies | View |